Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44])

The summary for the Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44]) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44]): Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to continue and expand non-clinical and pre-clinical efforts for product development of radiological/nuclear medical countermeasures effective for 1) the mitigation or treatment of acute radiation syndromes and long-term or delayed effects, 2) the treatment of internal radionuclide contamination with decorporation agents, and 3) the determination of individual radiation exposure levels with radiation biodosimetry products for potential use during a radiological emergency.Applications proposing candidate product(s) that mitigate and/or treat acute and long-term radiation injury due to lethal exposures or facilitate the elimination of internal radionuclide contamination; or that propose means of accurately estimating radiation dose received (biodosimetry) are solicited.Applications should support product development efforts leading to the submission of Investigational New Drug Applications (IND) or Investigational Device Exemptions (IDE) to the U.S. Food and Drug Administration (FDA) to facilitate eventual licensure and potential inclusion in the Strategic National Stockpile (SNS). Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I and Phase II applications.
Federal Grant Title: Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR[R43/R44])
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PA-09-093
Type of Funding: Grant
CFDA Numbers: 93.855
CFDA Descriptions: Allergy, Immunology and Transplantation Research
Current Application Deadline: Jan 07, 2012
Original Application Deadline: Jan 07, 2012
Posted Date: Feb 09, 2009
Creation Date: Feb 09, 2009
Archive Date: Feb 07, 2012
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Small businesses
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants
• Immune Tolerance Network (UM1 Clinical Trial Required)
• Accelerating Research and Development of Next Generation Vaccines against Malaria - a Mode...
• Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)
• Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
• Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional)
• Center for HIV/AIDS Vaccine Immunology (CHAVI)
• Genomics of Transplantation Cooperative Research Program
• Asthma and Allergic Diseases Cooperative Research Centers
More Grants from the National Institutes of Health
• HIV/AIDS Clinical Trials Network Statistical and Data Management Centers (UM1 Clinical Tri...
• HIV/AIDS Clinical Trials Network Laboratory Centers (UM1 Clinical Trial Required)
• HIV/AIDS Clinical Trials Network Clinical Trials Units (UM1 Clinical Trial Required)
• HIV/AIDS Clinical Trials Network Leadership and Operations Centers (UM1 Clinical Trial Req...
• Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional D...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2026 FederalGrants.com